Starbucks Raises 2026 Outlook as Turnaround Strategy Boosts Sales and Earnings 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Seagate Stock Surges After Strong Q3 Earnings Beat and Bullish Outlook 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Pershing Square Raises $5 Billion in Landmark U.S. IPO and Share Placement 
SCHAUMBURG, Ill., Feb. 03, 2016 -- Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced that it will release financial results for the 2015 fourth quarter and full year pre-market on Tuesday, February 16, 2016 and will host a teleconference and webcast at 9 a.m. ET to review the results.
Interested parties may access the live call by dialing:
Within the United States: 877-293-5456
International: 707-287-9357
A live webcast of the teleconference will be available on the company's website at: http://investor.sagentpharma.com/events.cfm.
A replay of the presentation will be available on the Sagent website or by dialing:
Toll-Free: 855-859-2056
Passcode: 45341464
The replay will be available until February 29, 2016.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc., founded in 2006, is a global specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique, global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.
INVESTOR CONTACT: Jonathon Singer, Sagent 847-908-1605 [email protected]
